(JXN) Jackson Financial - Overview
Stock: Annuities, Life Insurance, Investment Contracts
| Risk 5d forecast | |
|---|---|
| Volatility | 38.5% |
| Relative Tail Risk | -6.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.99 |
| Alpha | 10.69 |
| Character TTM | |
|---|---|
| Beta | 1.366 |
| Beta Downside | 1.668 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.09% |
| CAGR/Max DD | 1.17 |
EPS (Earnings per Share)
Revenue
Description: JXN Jackson Financial January 08, 2026
Jackson Financial Inc. (NYSE:JXN) operates a diversified annuity platform for U.S. retail investors, organized into three segments: Retail Annuities, Institutional Products, and Closed Life & Annuity Blocks. The Retail Annuities line sells variable, fixed-index, fixed, and payout annuities plus registered index-linked and lifetime income solutions. Institutional Products deliver guaranteed investment contracts, funding agreements tied to the Federal Home Loan Bank program, and medium-term funding-agreement-backed notes. The Closed Life segment offers whole life, universal life, variable universal life, term life policies, and group payout annuities, complemented by investment-management services. Distribution is broad, encompassing independent broker-dealers, wirehouses, regional brokers, banks, RIAs, third-party platforms, and insurance agents.
Recent filings show FY 2023 revenue of roughly $1.2 billion with a net income margin of ~5%, reflecting the low-margin nature of annuity underwriting. The business is highly interest-rate sensitive: rising yields improve the spread on fixed-index products but can suppress demand for fixed annuities as investors seek higher-yield alternatives. Demographic trends-particularly the aging of the Baby-Boom cohort-remain a tailwind for retirement-income solutions, while the broader diversified-financial-services sector is pressured by tightening capital requirements and heightened competition from fintech-enabled wealth platforms.
For a deeper, data-driven view of JXN’s valuation dynamics and scenario analysis, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 16.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.14 > 1.0 |
| NWC/Revenue: 542.6% < 20% (prev 1593 %; Δ -1051 % < -1%) |
| CFO/TA 0.02 > 3% & CFO 5.66b > Net Income 16.0m |
| Net Debt (2.03b) to EBITDA (319.0m): 6.36 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.3m) vs 12m ago -5.57% < -2% |
| Gross Margin: 49.11% > 18% (prev 0.77%; Δ 4834 % > 0.5%) |
| Asset Turnover: 1.90% > 50% (prev 0.91%; Δ 0.99% > 0%) |
| Interest Coverage Ratio: 0.08 > 6 (EBITDA TTM 319.0m / Interest Expense TTM 100.0m) |
Altman Z'' 0.75
| A: 0.10 (Total Current Assets 50.65b - Total Current Liabilities 14.96b) / Total Assets 352.59b |
| B: 0.02 (Retained Earnings 7.47b / Total Assets 352.59b) |
| C: 0.00 (EBIT TTM 8.00m / Avg Total Assets 345.52b) |
| D: 0.01 (Book Value of Equity 5.00b / Total Liabilities 342.24b) |
| Altman-Z'' Score: 0.75 = B |
Beneish M
| DSRI: none (Receivables none/21.95b, Revenue 6.58b/3.09b) |
| GMI: 1.57 (GM 49.11% / 77.30%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 2.13 (Revenue 6.58b / 3.09b) |
| TATA: -0.02 (NI 16.0m - CFO 5.66b) / TA 352.59b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of JXN shares?
Over the past week, the price has changed by -0.14%, over one month by -0.41%, over three months by +23.19% and over the past year by +43.30%.
Is JXN a buy, sell or hold?
- StrongBuy: 0
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the JXN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 122 | 5.5% |
| Analysts Target Price | 122 | 5.5% |
JXN Fundamental Data Overview February 21, 2026
P/S = 1.1854
P/B = 0.7973
Revenue TTM = 6.58b USD
EBIT TTM = 8.00m USD
EBITDA TTM = 319.0m USD
Long Term Debt = 2.03b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.03b USD (from netDebt column, last quarter)
Enterprise Value = 4.25b USD (7.92b + Debt 2.03b - CCE 5.70b)
Interest Coverage Ratio = 0.08 (Ebit TTM 8.00m / Interest Expense TTM 100.0m)
EV/FCF = 0.75x (Enterprise Value 4.25b / FCF TTM 5.66b)
FCF Yield = 133.3% (FCF TTM 5.66b / Enterprise Value 4.25b)
FCF Margin = 86.09% (FCF TTM 5.66b / Revenue TTM 6.58b)
Net Margin = 0.24% (Net Income TTM 16.0m / Revenue TTM 6.58b)
Gross Margin = 49.11% ((Revenue TTM 6.58b - Cost of Revenue TTM 3.35b) / Revenue TTM)
Gross Margin QoQ = none% (prev 27.58%)
Tobins Q-Ratio = 0.01 (Enterprise Value 4.25b / Total Assets 352.59b)
Interest Expense / Debt = 1.23% (Interest Expense 25.0m / Debt 2.03b)
Taxrate = 21.0% (US default 21%)
NOPAT = 6.32m (EBIT 8.00m * (1 - 21.00%))
Current Ratio = 3.39 (Total Current Assets 50.65b / Total Current Liabilities 14.96b)
Debt / Equity = 0.20 (Debt 2.03b / totalStockholderEquity, last quarter 9.95b)
Debt / EBITDA = 6.36 (Net Debt 2.03b / EBITDA 319.0m)
Debt / FCF = 0.36 (Net Debt 2.03b / FCF TTM 5.66b)
Total Stockholder Equity = 10.21b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.00% (Net Income 16.0m / Total Assets 352.59b)
RoE = 0.16% (Net Income TTM 16.0m / Total Stockholder Equity 10.21b)
RoCE = 0.07% (EBIT 8.00m / Capital Employed (Equity 10.21b + L.T.Debt 2.03b))
RoIC = 0.04% (NOPAT 6.32m / Invested Capital 14.31b)
WACC = 8.91% (E(7.92b)/V(9.95b) * Re(10.95%) + D(2.03b)/V(9.95b) * Rd(1.23%) * (1-Tc(0.21)))
Discount Rate = 10.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -6.23%
[DCF Debug] Terminal Value 74.99% ; FCFF base≈5.76b ; Y1≈5.82b ; Y5≈6.30b
Fair Price DCF = 1350 (EV 93.81b - Net Debt 2.03b = Equity 91.78b / Shares 68.0m; r=8.91% [WACC]; 5y FCF grow 0.76% → 2.90% )
EPS Correlation: 59.35 | EPS CAGR: 14.79% | SUE: 0.85 | # QB: 1
Revenue Correlation: 3.36 | Revenue CAGR: -2.77% | SUE: -0.38 | # QB: 0
EPS next Quarter (2026-03-31): EPS=6.10 | Chg30d=+0.261 | Revisions Net=+3 | Analysts=1
EPS current Year (2026-12-31): EPS=24.33 | Chg30d=+0.094 | Revisions Net=+5 | Growth EPS=+7.3% | Growth Revenue=+15.5%
EPS next Year (2027-12-31): EPS=26.81 | Chg30d=+0.231 | Revisions Net=+3 | Growth EPS=+10.2% | Growth Revenue=+4.3%